In heart failure risk assessment, ECV is higher in at-risk patients (31.3%) than in controls (27.1%) and correlates with NT-proBNP (r = 0.629) and left atrial volume, suggesting its utility as an early biomarker of myocardial changes [23]. Here, NPPB is linked to heart failure.